The long term goal of the research program is to understand the biochemical and genetic regulation of lipid metabolism and membrane homeostasis in bacteria. The basic blueprint for bacterial membrane lipid biosynthesis is established by decades of research with Escherichia coli. However, there are numerous and significant differences in lipid metabolism between Gram-positive and Gram-negative bacteria. Gram-positive bacteria have unique enzymes for fatty acid biosynthesis, use a different activated fatty acid intermediate and acyltransferase system, and use transcriptional regulators that are distinctly different from E. coil. The medical significance of understanding this vital facet of intermediary metabolism has focused the research plan on investigating fatty acid and phospholipid synthesis in two important human pathogens: Staphylococcus aureus and Streptococcus pneumoniae. These organisms represent two major branches of lipid metabolic diversity in Gram-positive bacteria. Because type II fatty acid synthesis is a vital facet of bacterial physiology, there is considerable interest in the therapeutic potential of pathway inhibitors. However, Gram-positive bacteria can utilize extracellular fatty acids and may circumvent pathway inhibitors by the acquisition of host-derived fatty acids.
One aim i s to identify and characterize the unknown enzymes in the pathway for the incorporation of exogenous fatty acids in Gram-positive bacteria. A detailed biochemical understanding of this process will allow us to determine if exogenous fatty acids can overcome fatty acid synthesis inhibitors.
The second aim i s to determine the mechanism for skin antibacterial defense by fatty acid intoxication. Fatty acids have been known for decades to be a component of the innate defense system and toxic to Gram-positive bacteria. We propose a completely new mechanism of action for skin fatty acids. Fatty acid intoxication arises from the inability of specific structures to be utilized by the enzymes of lipid metabolism resulting in the accumulation of intracellular fatty acids and the collapse of the membrane proton gradient. A mechanistic understanding of this important host defense mechanism will provide a rational basis for designing novel fatty acid structures with increased efficacy. The final goal is to identify the regulatory factors and target proteins responsible for the tight biochemical control of membrane lipid biosynthesis in Gram-positive pathogens. Fatty acid synthesis is stringently regulated at the biochemical level to ensure a balanced membrane lipid composition. A system- oriented metabolomics approach will be developed to study pathway regulation. The analysis of pathway intermediates following physiological perturbations will identify the candidate regulatory ligands and target enzymes that will be biochemically characterized. The systematic analytical workflow we will develop can be applied to study any bacterium, and the outcome of these studies in pathogens will suggest a unique approach to developing new therapeutics. Structural mimics of the key regulatory ligand(s) could be developed to block membrane lipid biosynthesis.

Public Health Relevance

The rapid increase in infections caused by drug-resistant pathogens lends urgency to the development of effective new antibiotic countermeasures. Fatty acid biosynthesis is a vital facet of bacterial physiology that offers promising targets for the development of novel therapeutics. This research will provide a definitive answer regarding the suitability of membrane lipid synthesis in Gram-positive pathogens as a target for novel antibacterial drug discovery development.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM034496-29
Application #
8389581
Study Section
Prokaryotic Cell and Molecular Biology Study Section (PCMB)
Program Officer
Chin, Jean
Project Start
1984-12-01
Project End
2014-11-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
29
Fiscal Year
2013
Total Cost
$690,498
Indirect Cost
$295,928
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Parsons, Joshua B; Broussard, Tyler C; Bose, Jeffrey L et al. (2014) Identification of a two-component fatty acid kinase responsible for host fatty acid incorporation by Staphylococcus aureus. Proc Natl Acad Sci U S A 111:10532-7
Yao, Jiangwei; Abdelrahman, Yasser M; Robertson, Rosanna M et al. (2014) Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis. J Biol Chem 289:22365-76
Zheng, Zhong; Parsons, Joshua B; Tangallapally, Rajendra et al. (2014) Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening. Bioorg Med Chem Lett 24:2585-8
Parsons, Joshua B; Frank, Matthew W; Jackson, Pamela et al. (2014) Incorporation of extracellular fatty acids by a fatty acid kinase-dependent pathway in Staphylococcus aureus. Mol Microbiol 92:234-45
Yao, Jiangwei; Rock, Charles O (2013) Phosphatidic acid synthesis in bacteria. Biochim Biophys Acta 1831:495-502
Parsons, Joshua B; Frank, Matthew W; Rosch, Jason W et al. (2013) Staphylococcus aureus fatty acid auxotrophs do not proliferate in mice. Antimicrob Agents Chemother 57:5729-32
Parsons, Joshua B; Rock, Charles O (2013) Bacterial lipids: metabolism and membrane homeostasis. Prog Lipid Res 52:249-76
Parsons, Joshua B; Kukula, Maciej; Jackson, Pamela et al. (2013) Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother 57:2182-90
Parsons, Joshua B; Frank, Matthew W; Subramanian, Chitra et al. (2011) Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc Natl Acad Sci U S A 108:15378-83
Kingston, Anthony W; Subramanian, Chitra; Rock, Charles O et al. (2011) A ?W-dependent stress response in Bacillus subtilis that reduces membrane fluidity. Mol Microbiol 81:69-79

Showing the most recent 10 out of 112 publications